References
- Bolard J, Legrand P, Heitz F, Cybulska B. (1991). One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochem 30:5707–15
- Croft SL, Sundar S, Fairlamb AH. (2006). Drug Resistance in Leishmaniasis. Clin Microbiol Rev 19:111–26
- Gershkovich P, Wasan EK, Lin M, et al. (2009). Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother 64:101–8
- Handman E, Bullen DV. (2002). Interaction of Leishmania with the host macrophage. Tren Parasitol 1:332–4
- Hartsel S, Bolard J. (1996). Amphotericin B, new life for an old drug. Tren Pharmacol Sci 17:446–9
- Iqbal J, Hira PR, Saroj G, et al. (2002). Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol 40:475–9
- Kreuter J. (2005). Liposomes and nanoparticles as vehicles for antibiotics. Infection 19:224–8
- Mc Conville MJ, Mullin KA, Ilgoutz SC, Teasdale RD. (2002). Regulated degradation of ER membrane proteins in a novel tubular lysosome in Leishmania mexicana. Microbiol Mol Biol Rev 66:122–54
- Muller RH, Jacobs C, Kayser O. (2001). Nano-suspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3–19
- Mundargi RC, Babu VR, Rangaswamy V, et al. (2008). Nano/micro technologies for delivering macromolecular therapeutics using poly (D,L-lactide-co-glycolide) and its derivatives. J Control Release 25:193–209
- Späth GF, Garraway LA, Turco SJ, Beverley SM. (2003). The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A 100:9536–41
- Sundar S, More DK, Singh MK, et al. (2000). Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104–7
- World health organization. (1999). Wkly Epidemiol Rec 74:365–76
- Yoshiaki K. (2001). Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev 47:1–2